The new and re-elected Board members will serve from 1 January for a term of three years
The UK's BioIndustry Association (BIA) has appointed Mark Bodmer, Vice President, Head of Immunology, UCB; Charles Brigden, Senior Vice President and Head of Business Development, BTG; Celia Caulcott, Executive Director, Innovation and Skills, BBSRC; and Keith Thompson, Chief Executive, Cell Therapy Catapult to its Board of Directors.
In addition, Sam Williams, Chief Executive of Modern Biosciences, has been re-appointed to the Board.
The new and re-elected Board members will serve from 1 January 2015 for a term of three years.
Alongside these appointments, the BIA has also welcomed new Director of Public Affairs and Communications, Pamela Learmonth, and Chief Operating Officer, Nick Gardiner, to the team.
Steve Bates, BIA Chief Executive, commented: 'It’s been a great year for UK biotech, accompanied by a number of significant successes for the BIA in areas such as access to medicines, the recent expanded Research and Bolar Exemptions and being a leading partner in the formal establishment of the Medicines Manufacturing Industry Partnership (MMIP). These new appointments will enable the BIA to continue its work, supporting the UK as the leader in European biotech.'